Gomisin N enhances TRAIL-induced apoptosis via reactive oxygen species-mediated up-regulation of death receptors 4 and 5

International Journal of Oncology

Volumn 40, Issue 4, 2012, Pages 1058-1065

  Inoue, Hiroki ^a   Waiwut, Pornthip ^a   Saiki, Ikuo ^a   Shimada, Yutaka ^a   Sakurai, Hiroaki ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Death receptor; Gomisin N; Reactive oxygen species; Tumor necrosis factor related apoptosis inducing ligand

Indexed keywords

CASPASE 3; CASPASE 8; DEATH RECEPTOR 4; DEATH RECEPTOR 5; GOMISIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHISANDRA CHINENSIS; UPREGULATION;

APOPTOSIS; CELL LINE, TUMOR; CYCLOOCTANES; HELA CELLS; HUMANS; LIGNANS; POLYCYCLIC COMPOUNDS; REACTIVE OXYGEN SPECIES; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECOMBINANT PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; UP-REGULATION;

EID: 84858641174     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1299     Document Type: Article

References (38)

1. Sterbova H, Sevcikova P, Kvasnickova L, Glatz Z and Slanina J: Determination of lignans in Schisandra chinensis using micellar electrokinetic capillary chromatography. Electrophoresis 23: 253-258, 2002. (Pubitemid 34157092)
2. He X, Lian L and Lin L: Analysis of lignan constituents from Schisandra chinensis by liquid chromatography-electrospray mass spectrometry. J Chromatogr A 757: 81-87, 1997. (Pubitemid 27046960)
3. Min HY, Park EJ, Hong JY, Kang YJ, Kim SJ, Chung HJ, Woo ER, Hung TM, Youn UJ, Kim YS, Kang SS, Bae K and Lee SK: Antiproliferative effects of dibenzocyclooctadiene lignans isolated from Schisandra chinensis in human cancer cells. Bioorg Med Chem Lett 18: 523-526, 2008.
4. Choi MS, Kwon KJ, Jeon SJ, Go HS, Kim KC, Ryu JR, Lee JM, Han SH, Cheong JH, Ryu JH, Shin KH and Ko CY: Schizandra chinensis alkaloids inhibit lipopolysaccharide-induced inflammatory responses in BV2 microglial cells. J Biomol Tech 17: 47-56, 2009.
5. Oh SY, Kim YH, Bae DS, Um BH, Pan CH, Kim CY, Lee HJ and Lee JK: Anti-inflammatory effects of gomisin N, gomisin J, and schisandrin C isolated from the fruit of Schisandra chinensis. Biosci Biotechnol Biochem 74: 285-291, 2010.
6. Marek J and Slanina J: Gomisin N. Acta Cryst 54: 1548-1550, 1998.
7. Opletal L, Sovova H and Bartlova M: Dibenzo[a,c]cyclooctadiene lignans of the genus Schisandra: importance, isolation and determination. J Chromatogr B Analyt Technol Biomed Life Sci 812: 357-371, 2004. (Pubitemid 39535421)
8. Choi YW, Takamatsu S, Khan SI, Srinivas PV, Ferreira D, Zhao J and Khan IA: Schisandrene, a dibenzocyclooctadiene lignan from Schisandra chinensis: structure-antioxidant activity relationships of dibenzocyclooctadiene lignans. J Nat Prod 69: 356-359, 2006.
9. Kim SH, Kim YS, Kang SS, Bae K, Hung TM and Lee SM: Anti-apoptotic and hepatoprotective effects of gomisin A on fulminant hepatic failure induced by D-galactosamine and lipopolysaccharide in mice. J Pharmacol Sci 106: 225-233, 2008. (Pubitemid 351366341)
10. Yim SY, Lee YJ, Lee YK, Jung SE, Kim JH, Kim HJ, Son BG, Park YH, Lee YG, Choi YW and Hwang DY: Gomisin N isolated from Schisandra chinensis significantly induces antiproliferative and pro-apoptotic effects in hepatic carcinoma. Mol Med Rep 2: 725-732, 2009.
11. Waiwut P, Shin MS, Inujima A, Zhou Y, Koizumi K, Saiki I and Sakurai H: Gomisin N enhances TNF-α-induced apoptosis via inhibition of the NF-κB and EGFR survival pathways. Mol Cell Biochem 350: 169-175, 2011.
12. Mahmood Z and Shukla Y: Death receptors: targets for cancer therapy. Exp Cell Res 316: 887-899, 2010.
13. Wu GS: TRAIL as a target in anti-cancer therapy. Cancer Lett 285: 1-5, 2009.
14. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z and Schwall RH: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155-162, 1999.
15. Shankar S and Srivastava RK: Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. Drug Resist Updat 7: 139-156, 2004. (Pubitemid 38736066)
16. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P and Ashkenazi A: Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277: 818-821, 1997. (Pubitemid 27366733)
17. MacFarlane M: TRAIL-induced signalling and apoptosis. Toxicol Lett 139: 89-97, 2003.
18. Zhang L and Fang B: Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 12: 228-237, 2005. (Pubitemid 40315182)
19. Fandy TE and Srivastava RK: Trichostatin A sensitizes TRAIL-resistant myeloma cells by downregulation of the antiapoptotic Bcl-2 proteins. Cancer Chemother Pharmacol 58: 471-477, 2006. (Pubitemid 43999795)
20. LeBlanc HN and Ashkenazi A: Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 10: 66-75, 2003. (Pubitemid 36511833)
21. Wang S and El-Deiry WS: TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22: 8628-8633, 2003. (Pubitemid 38019198)
22. Takeda K, Stagg J, Yagita H, Okumura K and Smyth MJ: Targeting death-inducing receptors in cancer therapy. Oncogene 26: 3745-3757, 2007. (Pubitemid 46842709)
23. Zhou J, Lu GD, Ong CS, Ong CN and Shen HM: Andrographolide sensitizes cancer cells to TRAIL-induced apoptosis via p53-mediated death receptor 4 up-regulation. Mol Cancer Ther 7: 2170-2180, 2008.
24. Taniguchi H, Yoshida T, Horinaka M, Yasuda T, Goda AE, Konishi M, Wakada M, Kataoka K, Yoshikawa T and Sakai T: Baicalein overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance via two different cell-specific pathways in cancer cells but not in normal cells. Cancer Res 68: 8918-8927, 2008.
25. Prasad S, Ravindran J, Sung B, Pandey MK and Aggarwal BB: Garcinol potentiates TRAIL-induced apoptosis through modulation of death receptors and antiapoptotic proteins. Mol Cancer Ther 9: 856-868, 2010.
26. Li X, Wang JN, Huang JM, Xiong XK, Chen MF, Ong CN, Shen HM and Yang XF: Chrysin promotes tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induced apoptosis in human cancer cell lines. Toxicol In Vitro 25: 630-635, 2011.
27. Lee DH, Rhee JG and Lee YJ: Reactive oxygen species up-regulate p53 and Puma; a possible mechanism for apoptosis during combined treatment with TRAIL and wogonin. Br J Pharmacol 157: 1189-1202, 2009.
28. Ishiguro K, Ando T, Maeda O, Ohmiya N, Niwa Y, Kadomatsu K and Goto H: Ginger ingredients reduce viability of gastric cancer cells via distinct mechanisms. Biochem Biophys Res Commun 362: 218-223, 2007. (Pubitemid 47296314)
29. Frese S, Pirnia F, Miescher D, Krajewski S, Borner MM, Reed JC and Schmid RA: PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2. Oncogene 22: 5427-5435, 2003. (Pubitemid 37072197)
30. Lee KY, Park JS, Jee YK and Rosen GD: Triptolide sensitizes lung cancer cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by inhibition of NF-kappaB activation. Exp Mol Med 34: 462-468, 2002. (Pubitemid 36114364)
31. Inoue S, MacFarlane M, Harper N, Wheat LM, Dyer MJ and Cohen GM: Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ 11 (Suppl 2): S193-S206, 2004.
32. Palacios C, Yerbes R and Lopez-Rivas A: Flavopiridol induces cellular FLICE-inhibitory protein degradation by the proteasome and promotes TRAIL-induced early signaling and apoptosis in breast tumor cells. Cancer Res 66: 8858-8869, 2006. (Pubitemid 44449204)
33. Ganten TM, Koschny R, Haas TL, Sykora J, Li-Weber M, Herzer K and Walczak H: Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology 42: 588-597, 2005. (Pubitemid 41233651)
34. Shi RX, Ong CN and Shen HM: Protein kinase C inhibition and x-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells. Cancer Res 65: 7815-7823, 2005.
35. Zhang S, Shen HM and Ong CN: Down-regulation of c-FLIP contributes to the sensitization effect of 3,3′-diindolylmethane on TRAIL-induced apoptosis in cancer cells. Mol Cancer Ther 4: 1972-1981, 2005. (Pubitemid 43056980)
36. Son YG, Kim EH, Kim JY, Kim SU, Kwon TK, Yoon AR, Yun CO and Choi KS: Silibinin sensitizes human glioma cells to TRAIL-mediated apoptosis via DR5 up-regulation and down-regulation of c-FLIP and survivin. Cancer Res 67: 8274-8284, 2007.
37. Galligan L, Longley DB, McEwan M, Wilson TR, McLaughlin K and Johnston PG: Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP. Mol Cancer Ther 4: 2026-2036, 2005. (Pubitemid 43056986)
38. Jin Z, McDonald ER III, Dicker DT and El-Deiry WS: Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J Biol Chem 279: 35829-35839, 2004. (Pubitemid 39100590)